<DOC>
	<DOCNO>NCT01578304</DOCNO>
	<brief_summary>To evaluate efficacy safety 12 week oral administration Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg daily urge incontinence and/or increase urinary frequency associate urgency may occur patient overactive bladder .</brief_summary>
	<brief_title>Comparison Efficacy Safety Between Imidafenacin Fesoterodine Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Male female patient overactive bladder age 20 year subject continuo symptom 3 month subject prepare symptom diary deem eligible study investigator 8 time daily mean urination frequency 2 time daily mean frequency sense urinary urgency 2 time urge incontinence frequency subject clinically significant stress urge incontinence , patient urinary tract infection relapse urinary tract infection receive treatment 4 time previous year subject diseases prohibit anticholinergic administration subject use indwell catheter intermittent self intubation program , patient prostatic hyperplasia , prostatic cancer , bladder cancer , bladder stone , interstitial cystitis complication subject receive low urinary tract surgery within 6 month subject catheter place intermittent catheterization subject deem ineligible study investigator subinvestigator , pregnant woman , nurse woman , woman plan pregnancy use proper contraceptive study period subject within 1 month clinical study complete subject 100mL residual urine subject acute urinary retention history subject administer Prohibited concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Overactive bladder</keyword>
</DOC>